Abhishek Thavamani

Harvard Medical School and Beth Israel Deaconess Medical Center

Dr. Thavamani completed his PhD research through the International Max Planck Research School, at the University of Tubingen, Germany. His research focused on studying specific subtypes of liver carcinoma using mouse models, with a goal of developing novel treatment strategies. Since 2019, he has been pursuing his research as a post-doctoral fellow at the Beth Israel Deaconess Medical center and Harvard Medical School. His research currently focuses on developing/improving targeted therapy strategies for the treatment of triple negative breast cancer (TNBC). His research interests include, studying the heterogeneity of tumors and the surrounding microenvironment in vivo using novel-imaging technologies.

Maulik Vyas

Harvard Medical School and Massachusetts General Hospital

Dr. Maulik Vyas earned PhD in 2016 from the University of Cologne in Germany, where he developed novel bi- and tri-specific antibody-based recombinant constructs to harness Natural Killer (NK) cells against leukemia. He continued in the same lab as a postdoctoral scientist studying immune suppression by soluble factors within the ascites of ovarian cancer patients. In 2019, he joined the Cutaneous Biology Research Center at Massachusetts General Hospital and Harvard Medical School to study the regulation of NK cell effector functions in solid cancers. Using skin and breast cancer models, his efforts have been to identify novel components in the tumor microenvironment that modulate NK cell functions and to translate these findings to facilitate the development of immunotherapies against cancer.

Lin Wang

Harvard Medical School and Beth Israel Deaconess Medical Center

Dr. Wang received his PhD degree from the University of Science and Technology of China in 2018, and his research focused on cancer metabolism and cell cycle regulation during this period. He joined BIDMC in 2018 and continued the research on targeting cancer metabolism for combinational therapy with immune components modulation. He is experienced in using different ways to detect metabolic changes in cancer cells.

Steven Vandal

Harvard Medical School and Beth Israel Deaconess Medical Center

Dr. Vandal received his PhD in Physics in 2020 from the Worcester Polytechnic Institute in Massachusetts. As part of his graduate studies, he worked on simulations of cytoskeletal cargo transport to understand the bio-mechanical properties of molecular motors. In 2021, he joined Beth Israel Deaconess Medical Center in Boston, as a post-doctoral fellow. He currently studies the cellular metabolism of breast cancer in relation to the cytoskeletal network.